A broad biomarker panel that is capable of detecting AD and non-AD proteinopathies will be especially informative since it is now acknowledged that co-pathology with AD is rather common, particularly alpha-synuclein [4] and TDP-43 pathologies [5, 6]. This evidence concerns the gene TARDBP and Alzheimer disease.